Prospective evaluation of the G8 screening tool for prognostication of survival in elderly patients with lung cancer: A single-institution study

Abstract

The G8 questionnaire is a quick and easy-to-use screening tool. Several studies reported that the G8 questionnaire had a high sensitivity for predicting abnormalities in the full comprehensive geriatric assessment and predicted functional decline and survival in elderly cancer patients. The present study aimed to evaluate the role of the G8 questionnaire for predicting clinical outcomes and overall survival (OS) in elderly patients with lung cancer, who received chemotherapy or chemoradiotherapy. The data of 101 lung cancer patients aged ≥70 years, who were hospitalized between September 2011 and August 2014, were analyzed. Of these patients (median age, 77 years), 83 (82%) had impaired G8 scores. The proportion of patients with an impaired G8 score was significantly higher in patients aged ≥80 years than those aged <80 years (p = 0.04). All 18 patients with a normal G8 score possessed an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1, and none of the patients with a normal G8 score had an ECOG PS of ≥2 (p < 0.0001). An impaired G8 score tended to correlate with a relative dose intensity of <0.65 in patients who received chemotherapy or chemoradiotherapy (p = 0.05, odds ratio = 5.40). In the univariate analysis, an ECOG PS of ≥2 and an impaired G8 score were significantly associated with a poor OS (p = 0.009 and p = 0.003, respectively). Moreover, in the multivariate analysis, an ECOG PS of ≥2 (HR 2.55; 95% CI, 1.23–5.30; p = 0.01) and an impaired G8 score (HR 3.86; 95% CI, 1.44–13.36; p = 0.006) were remained independent prognostic factor for OS. G8 screening tool is useful for the prognostication of elderly lung cancer patients treated with chemotherapy. These finding suggest that the G8 questionnaire could be a useful tool in treatment decision-making to predict prognosis and prevent patients from receiving inappropriate anti-cancer treatment near the end of life.

<p>Clinical Outcomes and Safety of Apatinib Mesylate in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Patients Who Progressed After Standard Therapy and Analysis of the <em>KDR</em> Gene Polymorphism</p>

“…The influence of the ECOG score on patient prognosis has been confirmed in numerous studies; high scores have been associated with worse prognosis. 26 However, the clinical outcomes of other retrospective analyses of apatinib mesylate in the treatment of NSCLC were consistent with the results of the present study. 27,28 Interestingly, the mOS in our study was 10.05 months, which was slightly longer than that reported in other research studies of apatinib mesylate.…”

Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the VEGFR2 polymorphism

“…Furthermore, patients with an ECOG score of 2 were included in the present study, in contrast to the phase II clinical trial, where these patients were excluded. However, the clinical significance of ECOG score has been confirmed in previous studies, suggesting that the higher the score, the worse the prognosis (35,36). In the present study, the results of Cox's regression analysis indicated that patients with a score of 1-2 were associated with a worse prognosis.…”

The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen

“…As far as we know, higher ECOG score conferred worse prognosis in patients with NSCLC. 37 And the results of multivariate Cox analysis suggested that patients with ECOG 1∼2 score were associated with worse prognosis compared with those with 0 score. The clinical outcomes of the 169 patients with NSCLC receiving bevacizumab combined with platinum-based chemotherapy in this study provided real-world evidence for bevacizumab administration in patients with NSCLC.…”